Regeneron Pharmaceuticals Inc
NASDAQ:REGN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
775.18
1 201.76
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one REGN stock under the Base Case scenario is hidden USD. Compared to the current market price of 935.42 USD, Regeneron Pharmaceuticals Inc is hidden .
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Regeneron Pharmaceuticals Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for REGN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Sign up to unlock intrinsic valuation and risk & rewards analysis.
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Regeneron Pharmaceuticals Inc., based in Tarrytown, New York, has established itself as a powerhouse in the biopharmaceutical industry, primarily focusing on the development of innovative treatments for serious medical conditions. Founded in 1988, the company has built a robust pipeline of cutting-edge drugs that address a variety of diseases, including eye disorders, cancer, and autoimmune diseases. Regeneron's flagship product, Eylea, has transformed the treatment of retinal diseases, generating significant revenue and proving the company's capability to bring breakthrough therapies to market. The company's strong commitment to research and development is complemented by its proprietary Ve...
Revenue & Expenses Breakdown
Regeneron Pharmaceuticals Inc
Balance Sheet Decomposition
Regeneron Pharmaceuticals Inc
Current Assets | 19.1B |
Cash & Short-Term Investments | 9.8B |
Receivables | 5.7B |
Other Current Assets | 3.6B |
Non-Current Assets | 17B |
Long-Term Investments | 7.7B |
PP&E | 4.3B |
Intangibles | 1.1B |
Other Non-Current Assets | 3.9B |
Current Liabilities | 3.5B |
Accounts Payable | 561.7m |
Accrued Liabilities | 2.4B |
Other Current Liabilities | 586m |
Non-Current Liabilities | 4.4B |
Long-Term Debt | 2.7B |
Other Non-Current Liabilities | 1.7B |
Earnings Waterfall
Regeneron Pharmaceuticals Inc
Revenue
|
13.5B
USD
|
Cost of Revenue
|
-1.8B
USD
|
Gross Profit
|
11.7B
USD
|
Operating Expenses
|
-7.5B
USD
|
Operating Income
|
4.2B
USD
|
Other Expenses
|
123.6m
USD
|
Net Income
|
4.3B
USD
|
Free Cash Flow Analysis
Regeneron Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
Regeneron delivered a strong Q2 2024 with a 12% rise in total revenues to $3.5 billion, driven by robust sales of EYLEA HD and its continued success globally. Earnings per share grew 13% to $11.56, indicating healthy profitability. The company saw significant growth in its collaboration with Sanofi, particularly through DUPIXENT, which showed a 29% revenue increase. Additionally, LIBTAYO sales surged by 43% due to strong demand in oncology. Regeneron's pipeline remains promising with upcoming Phase III trials and regulatory decisions. The firm expects continued revenue growth and maintained its gross margin guidance at 89% for 2024.
What is Earnings Call?
REGN Profitability Score
Profitability Due Diligence
Regeneron Pharmaceuticals Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
Regeneron Pharmaceuticals Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.
REGN Solvency Score
Solvency Due Diligence
Regeneron Pharmaceuticals Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
Regeneron Pharmaceuticals Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
REGN Price Targets Summary
Regeneron Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for REGN is 1 191.06 USD with a low forecast of 828.2 USD and a high forecast of 1 365 USD.
Dividends
Current shareholder yield for REGN is hidden .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
REGN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 10,368 full-time employees. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. The firm's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. Its product candidates in clinical development include REGN4018, REGN5668, and Fasinumab, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one REGN stock under the Base Case scenario is hidden USD.
Compared to the current market price of 935.42 USD, Regeneron Pharmaceuticals Inc is hidden .